NeoPsy Systems

NeoPsy Systems was a biotechnology company dedicated to discovering novel treatments for central nervous system (CNS) disorders through the study of intracellular signaling. Founded by Nobel Laureate Dr. Paul Greengard, the company utilized a proprietary drug discovery platform that combined functional genomics and proteomics to identify unique therapeutic targets. Its research focused on modulating neurotransmitter pathways, specifically targeting phosphodiesterases and dopamine receptors to treat conditions like schizophrenia and Parkinson's disease. In 2002, NeoPsy Systems was acquired by Intra-Cellular Therapies, Inc., where its foundational technology led to the development and eventual commercialization of lumateperone (Caplyta). The company is recognized for its significant contribution to the understanding of molecular signaling in the brain.